KRAS and cancer: A shRNA-drug screen strategy identified some of these genes and the anti-apoptotic BH3 family gene BCL-XL (B-cell lymphoma extra-large) appeared as a hit suggesting that a BCL-XL/MEK inhibition could be a potential therapeutic approach for K-RAS mutant cancers [37].